Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone Receptor Positive Advanced Breast Cancer

Condition:   Breast Neoplasm Female Interventions:   Drug: CDK 4/6 inhibitor;   Drug: Non-Steroidal Aromatase Inhibitor;   Drug: Fulvestrant Sponsor:   Borstkanker Onderzoek Groep Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Source: OncoTargets and Therapy - Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
Authors: Sasano H, Miki Y, Fukuda T, Nagasaki S, Nakata T, Suzuki T Abstract Aromatase inhibitors have become the gold standard of endocrine therapy in postmenopausal patients with estrogen receptor-positive or estrogen-dependent breast carcinoma, replacing tamoxifen. However, it is true that there are some potential problems to be overcome or improved on regarding aromatase inhibitor treatment of breast cancer. This especially includes the presence of the estrogen receptor-positive patients who do not necessarily respond to aromatase inhibitors, may require other modes of endocrine therapy and develop resistance t...
Source: Expert Review of Endocrinology and Metabolism - Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research
In conclusion, there results of the present study indicated that suppression of BAG‑1 expression may activate the phosphoinositide 3‑kinase/Akt/mTOR pathway and protect ER‑positive breast cancer cells from tamoxifen‑induced inhibition of proliferation. ER‑positive breast cancer cells exhibiting low BAG‑1 expression appeared to be more sensitive to treatment with the mTOR inhibitor rapamycin. Furthermore, the results indicated that combination treatment targeting ER with tamoxifen and targeting mTOR with rapamycin may significantly potentiate the inhibitory effect in BAG‑1‑silenced cells. PMID: 3074...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Approximately two thirds of all breast cancer cases are estrogen receptor (ER)–positive. The treatment of this breast cancer subtype with endocrine therapies is effective in the adjuvant and recurrent settings. However, their effectiveness is compromised by the emergence of intrinsic or acquired resistance. Thus, identification of new molecular targets can significantly contribute to the development of novel therapeutic strategies. In recent years, many studies have implicated aberrant levels of translation initiation factors in cancer etiology and provided evidence that identifies these factors as promising therapeu...
Source: Journal of Biological Chemistry - Category: Chemistry Authors: Tags: Signal Transduction Source Type: research
ConclusionILC patients could derive significant DFS and OS benefits from CT, especially for high-risk patients.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
PET imaging with fluoro furanyl norprogesterone (FFNP) could provide a new...Read more on AuntMinnie.comRelated Reading: JNM: Imaging agents predict endocrine therapy response
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
AbstractPurposeTo evaluate the impact of chemotherapy on subjective cognitive functioning according to age in a large cohort of breast cancer patients.MethodsWithin the UMBRELLA cohort, 715 patients with early-stage primary invasive breast cancer (T1-3N0-1M0) were selected. Subjective cognitive function was assessed by means of the EORTC QLQ-C30 up to 24  months and compared between patients treated with and without chemotherapy, for three different age strata (355 patients   65 years). Differences between chemotherapy and non-chemotherapy patients by age at different time points were assessed ...
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
PMID: 30742565 [PubMed - as supplied by publisher]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: J Clin Oncol Source Type: research
Conclusion: Fulvestrant 500 mg was administered successfully to patients under daily practice conditions, and both medications were well tolerated. TTP was longest in patients treated with fulvestrant 500 mg 1 L compared with 2 L and 3 L in the palliative care setting.Breast Care
Source: Breast Care - Category: Cancer & Oncology Source Type: research
Next Generation ERα Inhibitors for Endocrine-Resistant ER+ Breast Cancers. Endocrinology. 2019 Feb 08;: Authors: Fanning SW, Greene GL Abstract One in eight women will be diagnosed with breast cancer in their lifetime. Because estrogen receptor alpha (ERα) is expressed in approximately 70% of patients, therapeutic intervention by ERα-targeted endocrine therapies remains the leading strategy to prevent progression/metastasis in the adjuvant setting. However, the efficacy of these therapies is diminished by the development of acquired resistance following prolonged treatment regiments....
Source: Endocrinology - Category: Endocrinology Authors: Tags: Endocrinology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Endocrine Therapy | Hormones